Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-0316 in EGFR T790M+ NSCLC
NCT03861156Phase 2Completed
- Sponsor
- InventisBio
- Start
- Feb 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by InventisBio. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2019; status: completed.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03861156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861156.